Stability of Propranolol Hydrochloride in SyrSpend SF
Author(s): Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
Issue: Nov/Dec 2012 - Volume 16, Number 6
View All Articles in Issue
Page(s): 513-515
Note: Electronic version includes errata or revisions.
Download in electronic PDF format for $75
Abstract: Propranolol hydrochloride is a beta blocker used to treat high blood pressure, abnormal heart rhythms, heart disease, pheochromocytoma, and certain types of tremors. Propranolol is marketed by Wyeth (now a part of Pfizer) and AstraZeneca under the brand names Inderal, Inderal LA, Avlocardyl, Deralin, Dociton, Inderalici, InnoPran XL, Sumial, Anaprilium, Bedranol SR (Sandoz). It is also available generically from several manufacturers. Propranolol hydrochloride is available as tablet, capsule, and oral liquid dosage forms in several strengths. Some patients are unable to tolerate oral tablets and capsules, challenging compounding pharmacies to seek alternative dosing options; namely oral solutions and suspensions. The objective of this study was to determine the stability of propranolol hydrochloride in SyrSpend SF. The drug was compounded into a 1-mg/mL suspension using SyrSpend SF and subsequently stored in a low actinic plastic prescription bottle at room temperature conditions. Six samples were assayed at each specific time point extending to 90 days by a stability-indicating high-performance liquid chromatography method. The method was validated for its specificity through forced-degradation studies. Based on the data collected, when protected from light at room temperature, the beyond-use date of propranolol hydrochloride in SyrSpend SF was shown to be at least 90 days.
Related Keywords:
Christine M. Geiger, MS, Mark A. Voudrie II, MS, PMP, Bridget Sorenson, BS, CAPM, propranolol hydrochloride, nonselective beta-adrenergic receptor inhibitor, beta blocker, hypertension, high blood pressure, arrhythmias, heart disease, angina, tremor, chest pain, oral suspension, stability
Related Categories:
EXCIPIENTS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, CARDIOLOGY, NEUROLOGY, STORAGE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Stability of Propranolol Hydrochloride in SyrSpend SF
Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
|
Nov/Dec 2012
Pg. 513-515
|
Propranolol Hydrochloride 1 mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 325
|
Propranolol Hydrochloride 1-mg/mL Injection
Allen Loyd V Jr
|
Jul/Aug 2014
Pg. 330
|
Propranolol Hydrochloride Capsules
Allen Loyd V Jr
|
Nov/Dec 2015
Pg. 513
|
Stability of Ursodiol in SyrSpend SF Cherry Flavored
Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
|
Nov/Dec 2012
Pg. 510-512
|
Stability of Verapamil Hydrochloride in SyrSpend SF Compared to Sorbitol Containing Syrup and Suspending Vehicles
Voudrie Mark A, Alexander Bridget, Allen D Brett
|
May/Jun 2011
Pg. 255-258
|
Propranolol 2 mg/mL and 5 mg/mL in Ora-Blend SF Suspension
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 148
|
Stability of Gabapentin in SyrSpend SF
Sorenson Bridget, Voudrie Mark A II, Gehrig Dan
|
Jul/Aug 2012
Pg. 347-349
|
Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
|
Nov/Dec 2007
Pg. 520-524
|
Propranolol Hydrochloride 1-mg/mL Oral Liquid
Allen Loyd V Jr
|
Jul/Aug 2006
Pg. 304
|
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF
Geiger Christine M, Sorenson Bridget, Whaley Paul
|
Sep/Oct 2015
Pg. 420-427
|
Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III, Everett Eric, Chamberlain Tyler
|
May/Jun 2020
Pg. 194-197
|
A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
|
Sep/Oct 2022
Pg. 364-368
|
Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry
Geiger Christine M, Sorenson Bridget, Whaley Paul A
|
Jul/Aug 2013
Pg. 344-346
|
Stability of Captopril in SyrSPend SF
Geiger Christine M, Sorenson Bridget, Whaley Paul A
|
Jul/Aug 2013
Pg. 336-338
|
Propranolol 2 mg/mL or 5 mg/mL in Ora-Sweet
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 504
|
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
|
Nov/Dec 2018
Pg. 516-526
|
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
|
Nov/Dec 2011
Pg. 458-463
|
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride
Zur Eyal
|
Sep/Oct 2011
Pg. 358-366
|
Stability of Omeprazole in SyrSpend SF Alka (Reconstituted)
Whaley Paul A, Voudrie Mark A II, Sorenson Bridget
|
Mar/Apr 2012
Pg. 164-166
|
Return to Top |